我要投票 同济堂在中草药行业中的票数:238
· 外 推 电 报 ·
2025-05-04 13:51:05 星期日

【同济堂是哪个国家的品牌?】

同济堂是什么牌子?「同济堂」是国药集团同济堂(贵州)制药有限公司旗下著名品牌。该品牌发源于贵州,由创始人朱鹤在2005-06-29期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力同济堂品牌出海!将品牌入驻外推网,定制同济堂品牌推广信息,可以显著提高同济堂产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

贵州同济堂制药有限公司是一家历史悠久的企业,是贵州中药行业闻名遐迩的老字号。同济堂始创于清光绪十四年(公元1888年),至今已有120多年的悠久历史。100多年来,同济堂把“同心协力,济世活人”作为永恒的精神,始终坚持传统中药特色,弘扬中华医药文化。以质量为优、便民服务之举而闻名省内外。是贵州省唯一获得国家授予“中华老字号”殊荣的医药企业。2008年,同济堂中药文化入选“第二批国家级非物质文化遗产”名录,成为国家重点保护的非物质文化遗产。

近年来,贵州同济堂已发展成为一家集科研、生产、销售、种植为一体,拥有贵州同济堂药品配送有限公司、贵州同济堂中药饮片有限公司、贵州同济堂药房连锁有限公司、贵州老来福药业、安徽精方药业、青海普兰特制药公司等十余家子公司的高科技集团化企业。在职员工3000多人。贵州同济堂制药有限公司现分别在贵阳市修文县和贵阳市小河区建立药品生产基地,通过GMP认证的生产线十一条,可生产胶囊剂、片剂、颗粒剂、锭剂、糖浆剂、酊剂、口服溶液剂、膏剂等十二种剂型。

目前,贵州同济堂制药有限公司有中西药品种达140多种,拥有自主知识产权的专利产品七个。其中11种现代化中药和59种西药列入《国家基本医疗保险和工伤保险药品目录》。

“仙灵骨葆胶囊”、“颈舒颗粒”、“润燥止痒胶囊”、“枣仁安神胶囊”和“风湿骨痛胶囊(片)”分别作为独家品种进入《2012版国家基本药物目录》。各产品凭借其确切而显著的疗效,在全国医药市场享有较高声誉,“同济堂”、“仙灵”、“仙灵骨葆”品牌已成为中国驰名商标。

2009年,美国信纳克医学研究中心关于“仙灵骨葆胶囊治疗绝经后骨质疏松症临床疗效研究”成果,在全球最权威的新英格兰杂志发表。这是首个关于中成药的循证医学国际权威机构认证结果。它标志着世界骨科治疗领域首次加入了中成药元素。中成药治疗骨病的历史从此掀开新的篇章。

在新产品研发方面,我们投入大量资金新建符合GLP要求的中心实验室用于新药的研制和现有药品的二次开发,研究人员为长期从事药物研究的专家、教授和专业技术人才,所开发药品技术含量高,疗效确切,为公司长远发展奠定了坚实的基础。

自1998年来,公司连续获得“贵阳市文明单位”、“贵阳市农业产业化重点龙头企业”、“贵州省纳税先进单位”、“贵州省区(县)先进企业”、“贵州省农业银行特级三A信用单位”、“贵阳市重合同守信用企业”、“贵阳市非公有制优势企业”等称号。“仙灵骨葆胶囊”填补了中成药治疗骨质疏松的空白,先后荣获“世界骨伤科联合会”科技进步一等奖、“中国骨伤科协会”特别贡献奖、贵州省优秀产品一等奖、“贵阳市科技创新一等奖”、“贵阳市科技创新特等奖”等诸多荣誉。

英文翻译:Guizhou Tongjitang Pharmaceutical Co., Ltd. is an enterprise with a long history, which is a famous time-honored brand in Guizhou traditional Chinese medicine industry. Tongjitang was founded in the 14th year of Guangxu in the Qing Dynasty (1888 AD), and has a long history of more than 120 years. For more than 100 years, Tongjitang has always adhered to the characteristics of traditional Chinese medicine and carried forward the Chinese medicine culture with the eternal spirit of "working together to save the world and the living". It is famous for its excellent quality and convenient service. It is the only pharmaceutical enterprise in Guizhou Province that has won the national award of "China time honored brand". In 2008, Tongjitang traditional Chinese medicine culture was selected into the list of "the second batch of national intangible cultural heritage", becoming a national key protected intangible cultural heritage. In recent years, Guizhou Tongjitang has developed into a high-tech group enterprise integrating scientific research, production, sales and planting, with more than ten subsidiaries including Guizhou Tongjitang Pharmaceutical Distribution Co., Ltd., Guizhou Tongjitang Herbal Pieces Co., Ltd., Guizhou Tongjitang pharmacy chain Co., Ltd., Guizhou Laolaifu Pharmaceutical Co., Ltd., Anhui Jingfang Pharmaceutical Co., Ltd., Qinghai plante Pharmaceutical Co., Ltd 。 More than 3000 employees. Guizhou Tongjitang Pharmaceutical Co., Ltd. has established drug production bases in Xiuwen County and Xiaohe District of Guiyang City, respectively. There are 11 GMP certified production lines, which can produce 12 dosage forms, including capsules, tablets, granules, pastilles, syrups, tinctures, oral solutions and plasters. At present, Guizhou Tongjitang Pharmaceutical Co., Ltd. has more than 140 kinds of Chinese and Western medicines and seven patented products with independent intellectual property rights. Among them, 11 kinds of modern Chinese medicine and 59 kinds of Western medicine are listed in the catalogue of national basic medical insurance and industrial injury insurance drugs. "Xianlinggubao capsule", "Jingshu Granule", "Runzaozhiyang capsule", "Zaoren Anshen capsule" and "Fengshigutong capsule (tablet)" were respectively included in the 2012 edition of national basic drug catalogue as exclusive varieties. Each product enjoys a high reputation in the national pharmaceutical market with its exact and significant curative effect, "Tongjitang", "Xianling", "Xianlinggubao" brand has become a well-known trademark in China. In 2009, the research results of "clinical efficacy of Xianlinggubao capsule in the treatment of postmenopausal osteoporosis" published in the most authoritative New England Journal. This is the first evidence-based medicine certification result about Chinese patent medicine. It marks the first time that traditional Chinese medicine has been added to the world orthopedic treatment field. The history of Chinese patent medicine treating osteopathy has opened a new chapter. In the aspect of new product research and development, we have invested a lot of money to build a new central laboratory that meets the requirements of GLP for the research and development of new drugs and the secondary development of existing drugs. The researchers have laid a solid foundation for the long-term development of the company for the experts, professors and professional technical personnel who have been engaged in drug research for a long time with high technical content and precise curative effect. Since 1998, the company has been awarded the titles of "Guiyang civilized unit", "key leading enterprise of agricultural industrialization in Guiyang", "advanced unit of tax payment in Guizhou Province", "advanced enterprise in Guizhou Province (county)", "special class 3A credit unit of Agricultural Bank of Guizhou Province", "contract abiding and credit abiding enterprise in Guiyang city", "non-public dominant enterprise in Guiyang city" and so on. "Xianlinggubao capsule" has filled in the blank of Chinese patent medicine in the treatment of osteoporosis. It has successively won the first prize of science and technology progress of "world Orthopedic Association", "special contribution award of China Orthopedic Association", "first prize of excellent products of Guizhou Province", "first prize of Science and technology innovation of Guiyang city", "special prize of science and technology innovation of Guiyang city" and many other honors.

本文链接: https://www.waitui.com/brand/678835060.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

巴菲特谈巨额现金储备

巴菲特在伯克希尔・哈撒韦股东大会上表示,伯克希尔现金数量确实是相当高,但好的机会不会每一天都出现。不正确或不正当的投资,反而会损害投资人的利益。巴菲特表示,他一直在寻找投资机会,并希望减少手头现金——可能降至500亿美元。事情偶尔会变得极具吸引力。重大交易“极不可能”明天就发生,但在五年内则并非如此。之所以赚了很多钱,是因为从未全仓投资。(财联社)

2小时前

巴菲特评价苹果CEO:“库克为伯克希尔赚的钱,比我为伯克希尔哈撒韦赚的还多。”

巴菲特在伯克希尔・哈撒韦股东大会上提到库克称,很高兴苹果CEO库克先生也到场了,在乔布斯逝世之后,库克接手苹果同样做得非常出色,没有人能像乔布斯一样,但库克对苹果也有很大建树。巴菲特打趣道,“说来有点难为情,库克为伯克希尔赚的钱,比我为伯克希尔哈撒韦赚的还多。”(财联社)

2小时前

年轻投资者如何塑造投资理念?巴菲特:与更优秀的人为伍

谈及年轻投资者应该如何塑造他们的投资理念时,巴菲特表示,你交往的人非常重要。“你应该和比你优秀的人在一起,”他说。“你会朝着你所交往的人的方向前进。”(财联社)

2小时前

全国运动装备市场规模将超6000亿元

受到赛事带动,大众的体育热情得以激发,运动消费市场的热度持续攀升。相关运动装备、户外装备的生产和销售出现明显增长。数据显示,今年五一小长假期间全国体育消费市场表现活跃,群众健康体育消费有望带动539.7亿元的消费支出,2025年全国运动装备市场规模将达6021亿元,同比增长14.2%。(央视新闻)

2小时前

工业和信息化部:加强通用大模型和行业大模型研发布局

记者近日从工业和信息化部获悉,下一步将加强通用大模型和行业大模型研发布局,加快建设工业领域高质量数据集。工业和信息化部总工程师谢少锋说,我国已形成了覆盖基础层、框架层、模型层、应用层的完整的人工智能产业体系,人工智能大模型在电子、原材料、消费品等行业加快落地,在研发设计、中试验证、生产制造、运营管理等环节得到应用。他说,制造业是人工智能技术产品落地应用的重要领域。下一步将全力推进人工智能赋能新型工业化,一手抓供给,一手抓应用,推动制造业的全流程、重点行业、重点产品的智能升级。同时,加快培育一批行业龙头企业和专精特新中小企业,建设人工智能开源社区,加快关键急需标准的研制。(新华社)

2小时前

本页详细列出关于同济堂的品牌信息,含品牌所属公司介绍,同济堂所处行业的品牌地位及优势。
咨询